Abdominal postoperative adhesions (APA) commonly occurs after abdominal surgeries and causes serious complications. Although numerous physical anti-adhesion barriers (AAB) are used as therapeutical interventions, There is a limit to expecting excellent treatment only with physical barriers. In order to overcome these limitations it is necessary to be able to simultaneously perform a drug delivery system as well as act as a physical barrier. Here, we produce two natural polymers, agarose film(AF) and CMC Sol(CS), cross-linked with different concentrations of citric acid(CA) to prepare an adhesion barrier and an intraperitoneal instillator. and we measured the physicochemical properties of CA-AF and CA-CS Next, Metformin(MET)and saponin(SAP),anti-inflammatory drug, was loaded in CA-AF and CA-CS, respectively. In order to determine the possibility of anti-adhesion, MET@CA-AF and SAP@CA-CS were applied to animal adhesion models to confirm the biological evaluation of adhesion.anti-inflammatory properties, was loaded in the CA-AFs yielding the MET-loaded CA-AF (MET@CA-AF) and the time-dependent MET release was monitored. Based on their physicochemical properties, MET@CA-AF containing 20% CA appeared a promising AAB candidate and wasfurther used in an in vivo study. Mouse models of PAA were established with cecum abrasion and the MET@CAAFand CA-AF were applied between the injured interfaces. At postoperative day 14, the therapeutic efficacieswere analyzed by using clinical adhesion scoring and quantification of collagen-I and fibroblasts in adhesion interfaces. The results showed that applications of MET@CA-AF or CA-AF for 14 days significantly attenuated the clinical adhesion score and thickness of adhesion interface. Furthermore, when compared with the group withoperation, the groups with MET@CA-AF or CA-AF exhibited the significant attenuation in PAA-associatedmyofibroblast activation in adhesion interface. Importantly, these attenuations were significantly more intensified in the group with MET@CA-AF than in the group with CA-AF. Based on our data, we anticipate that MET@CAAF,a novel synthesized drug-eluting AAB, can protect against PAA by exerting the dual role of physical barrier and MET-based pharmaceutic.